The complaint alleges that Replimune executives misled shareholders by failing to disclose critical regulatory hurdles regarding their Biologics License Application (BLA). According to the filing, the company allegedly ignored study design concerns raised by the FDA and relied on preliminary, limited data from an unplanned analysis of just 40 patients—a fraction of the 400-patient enrollment target. These omissions reportedly left the company vulnerable to federal rejection of their clinical data.

The lawsuit contends that the company’s public statements regarding its operational prospects lacked a reasonable basis, ultimately damaging investor confidence. Those who purchased Replimune shares during the specified window may contact the Law Offices of Howard G. Smith to discuss their legal options. Participation in the litigation does not require immediate action, as individual investors retain the right to choose their own counsel or remain as absent class members.